Mutations in TREM2 increase risk for late-onset AD. In this issue of Neuron, Zhao et al. (2018) show that TREM2 binds Ab to enhance its clearance and Lee et al. (2018) demonstrate that human TREM2 expression in AD mice ameliorates Ab-associated deficits.
As the leading cause of dementia in the elderly, Alzheimer's disease (AD) affects approximately 5% of people over 65 years of age and the prevalence further increases with aging. AD is characterized clinically by loss of memory, and pathologically by amyloid beta (Ab) deposition, accumulation of neurofibrillary tangles, gray matter atrophy, and extensive glial activation. Early-onset familial forms of AD (FAD) are caused by mutations in APP, PSEN1, and PSEN2 genes, which are all linked with Ab production. However, the majority of AD cases are sporadic late-onset AD (LOAD). Various innate immune-related genes expressed by microglia have been linked with elevated risk of LOAD in genome-wide association studies. More recently, wholeexome sequencing led to the discovery of rare mutations in triggering receptor expressed on myeloid cells 2 (TREM2), such as R47H, which increases the risk for LOAD by 2-to 3-fold (Guerreiro et al., 2013; Jonsson and Stefansson, 2013) . TREM2 is almost exclusively expressed by microglia in the brain, and has been shown to regulate microglial phagocytosis and response to inflammatory stimuli. Our understanding of how TREM2 mutations contribute to AD pathogenesis is still in its early stages. Most of the studies are informed by deletion mutants. Loss of TREM2 or TREM2 haploinsufficiency in AD mouse models diminished the number of plaque-associated microglia and exerted age-dependent effects on plaque deposition (Jay et al., 2017; Wang et al., 2015) . In this issue of Neuron, Zhao et al. (2018) and Lee et al. (2018) expand on these findings. They identify TREM2 as a bona fide Ab receptor that mediates various microglial responses to Ab, and provide additional insights into how TREM2 shapes microglial transcriptional responses and impacts microglia-plaque interaction and Ab-associated cognitive deficits.
To examine how elevating TREM2 affects AD-related deficits, Lee et al. (2018) utilize a bacterial artificial chromosome (BAC) transgene approach to drive expression of human TREM2 (BAC-TREM2) in wild-type and transgenic mice expressing APP and PSEN1 with FAD mutations (5XFAD), a widely used mouse model for AD. By driving TREM2 expression using its endogenous genomic elements, and with deletion of all the other TREM-like genes on the BAC, this approach represents a more physiological method for studying gene dosage effects without altering endogenous mouse TREM2 expression or the kinetics of TREM2 upregulation during AD. Indeed, the beneficial effects of BAC-TREM2 on disease-relevant phenotypes complement nicely with the detrimental effects induced by TREM2 deficiency (Yuan et al., 2016) . First, while TREM2 deficiency in 5XFAD mice resulted in an increase in plaques with longer and branched amyloid fibrils and more dystrophic neurites (Wang et al., 2015; Yuan et al., 2016) , increasing TREM2 gene dosage reduced plaque area and associated toxicity ( Figure 1A ). Compared to 5xFAD, 5xFAD/TREM2 brains show significantly lower insoluble and soluble Ab-42 levels and reduced plaque area at 4 and 7 months, respectively. Increasing TREM2 gene dosage also appears to remodel the plaque type toward more compact forms, which are associated with fewer dystrophic neurites. Second, comprehensive RNA sequencing (RNA-seq) analyses revealed that the transcriptional signature of 5xFAD/ TREM2 was shifted closer to that of wild-type mice, suggesting that elevating TREM2 expression promotes a partial restoration of the microglial profile ( Figure 1A ). Using differential gene expression and weighted gene correlation network analyses (WGCNAs), Lee et al. (2018) identify a subset of differentially expressed genes they term TREM2 dosagedependent (TD) genes. TD genes show altered kinetics of induction in 5xFAD/ TREM2 compared to 5xFAD brains. The majority of these TD genes have been previously implicated in microglia's response to neurodegenerative diseases and neuronal death (Krasemann et al., 2017) . Interestingly, TREM2 exhibits a bimodal effect on disease-associated TD genes. Genes involved in microglial homeostatic functions, such as phagocytosis and resolution of inflammation, show accelerated induction in 5xFAD/TREM2 compared to 5xFAD, while the expression of genes associated with neurodegeneration is delayed. While the mechanistic underpinnings of the bimodal TREM2-dependent signature in response to amyloid remain to be elucidated, results from Lee et al. strongly support TREM2 enhancement as a promising protective strategy against Ab deposition and toxicity. Further analyses and validation of microglial transcriptional networks responsive to TREM2 gene dosage could shed light on additional molecular insights and potential therapeutic targets.
The mechanism underlying the TREM2-plaque interaction has been a topic of intense investigation. Earlier studies have shown that lipids, highly enriched in plaques, are potent TREM2 ligands.
Specifically, lipids can activate TREM2 as components of a lipoprotein complex, such as apolipoprotein E and APOA1, APOB, and APOJ (Yeh et al., 2016) . Remarkably, Zhao et al. (2018) report Ab oligomer as a potent ligand for TREM2. TREM2 binds to Ab oligomers with nanomolar affinity to mediate Ab degradation and downstream signaling via phosphorylation of spleen tyrosine kinase (Syk) ( Figure 1B) . The direct Ab-TREM2 interaction was characterized using a combination of cell-free, solid phase, and cellbased binding assays, and confirmed with co-immunoprecipitation in AD mouse models and human brains. The binding of Ab activates TREM2 signaling to mediate microglial inflammatory responses and resting membrane potential (RMP) depolarization in cultured microglia. In contrast, Ab-induced inflammatory responses and RMP depolarization are abolished in TREM2 knockout (KO) microglia, which already exhibit a depolarized RMP. A more detailed investigation revealed the involvement of voltage-gated and inward rectifier potassium (K + ) channels in Ab-TREM2 signaling. Using whole-cell patch clamping, Zhao et al. (2018) show that Ab treatment reduces inward rectifier K + currents, an effect that is completely abolished in TREM2 KO microglia. Interestingly, TREM2 KO microglia already exhibit reduced inward rectifier K + currents, likely due to transcriptional downregulation, which could explain the depolarized RMP in these cells. Given the importance of K + current in modulating microglial excitability, proliferation, chemotaxis, and migration, it is highly conceivable that some of the functional consequences of the Ab-TREM2 interaction result from alterations in inward K + current and RMP. The next steps would be to directly investigate the roles of various K + channels in Ab-induced microglial responses that are TREM2 dependent. It is important to note that Ab internalization by microglia does not depend on TREM2, presumably due to presence of other Ab receptors. However, R47H and R62H mutations impair TREM2's Ab-binding ability, providing a potential mechanism by which TREM2 mutations elevate risk for LOAD. How R47H and R62H mutations alter TREM2-Ab signaling remains to be determined. Strikingly, both studies provide evidence that TREM2 alters the degradative process in microglia, albeit through disparate mechanisms. Zhao et al. (2018) show that TREM2 KO microglia retain internalized fluorescently labeled Ab longer than controls. They suggest that defective clearance of Ab in TREM2 KO microglia is caused primarily by aberrant proteasome function, with little contribution from lysosomes. Conversely, Lee et al. (2018) provide strong evidence for TREM2-mediated regulation of lysosomal degradation. First, there is increased lysosomal protein expression in plaqueassociated microglia in 5xFAD/TREM2 compared to 5xFAD brains. Additionally, many TD genes encoding lysosomal enzymes and other lysosome-associated proteins are increased in 5xFAD/TREM2. Given that intracellular plaque accumulation impairs microglial function and promotes inflammation, increased microglial turnover represents another possible mechanism of TREM2-associated plaque clearance. Zhao et al. (2018) show that TREM2 expression promotes microglial proliferation and apoptosis in response to Ab exposure. It is unclear if TREM2 gene dosage increases microglia turnover in 5xFAD/TREM2 brains and how this contributes to changes in plaque clearance. TREM2-mediated Ab degradation likely involves multiple mechanisms and future studies on the kinetic, molecular, and temporal regulation of these various pathways are needed. Nonetheless, these papers highlight that TREM2 is involved in all phases of Ab phagocytosis: its recognition, internalization, and clearance. Lee et al. (2018) also provide evidence of non-cell-autonomous effects of increasing TREM2 gene dosage. There is elevated expression of neuronal and synaptic genes in 5xFAD/TREM2 compared to 5xFAD brains, suggesting a partial rescue of neuronal cell loss. Indeed, they observe a significant reduction in the number of dystrophic neurites and a rescue of behavioral impairment in 5xFAD/TREM2 mice, as well as APP/ PS1;TREM2 mice. They also find a significant change in a WGCNA module enriched for astrocytic genes. It is unclear how TREM2 drives these non-cell-autonomous changes. One possibility is that TREM2 acts through its soluble form to impact neighboring cell types. Soluble TREM2 can be found on neurons and the AD-associated TREM2 mutation, R47H, results in reduced levels of neuronal-bound TREM2 (Song et al., 2018) . The consequences of this phenomenon on neuronal signaling remain to be determined. Alternatively, TREM2 could mediate non-cell-autonomous changes by altering the microglial secretome, which was highlighted by gene expression data from both groups. It would be interesting to functionally interrogate neuronal gene expression modules that show TREM2 gene dosage response to gain insights into TREM2-mediated rescue of neuronal dystrophy.
Future studies characterizing the findings presented in both papers in the context of the R47H mutation are greatly needed. It remains to be seen if the R47H mutation phenocopies loss of TREM2 or results in gain of toxic function in terms of microglial signaling and molecular responses to Ab. Data presented here and by others show impaired Ab binding and altered TREM2 intracellular distribution and degradation in cells expressing R47H-TREM2, suggesting some loss of TREM2 function. Identifying mechanistic convergences and divergences in various models of TREM2 will greatly inform development of efficacious therapeutic strategies targeting microglia. In addition, the question remains as to the effect of TREM2 gene dosage on tau pathology. Discoveries from Lee et al. (2018) and Zhao et al. (2018) greatly advance our understanding on the nature and the consequences of Ab-TREM2 binding, as well as how TREM2 gene dosage modulates microglia response and AD pathology. Taken together, these findings support the development of TREM2 enhancers as therapeutic strategies to protect against amyloid-associated toxicity in AD.
